Protein Biomarker Identified for Aggressive Neuroendocrine Carcinomas Diagnosis
New research is guiding the development of blood tests to detect and monitor responses to therapies in neuroendocrine carcinomas patients.
Read MorePosted by Andy Lundin | Jan 29, 2024 | Unknown Origin & Other Cancer Types |
New research is guiding the development of blood tests to detect and monitor responses to therapies in neuroendocrine carcinomas patients.
Read MorePosted by Andy Lundin | Jan 22, 2024 | Prostate |
A new study has found that rectal examination has no advantages over the PSA blood test for detecting prostate cancer.
Read MorePosted by Andy Lundin | Jan 16, 2024 | Lung Cancer |
The epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read MorePosted by Chris Wolski | Jan 12, 2024 | Digital Pathology |
By examining the UK’s technology-centric strategy and response, nations can right-size the practice of pathology and prepare for the future.
Read MorePosted by Andy Lundin | Jan 10, 2024 | Prostate |
Researchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma.
Read More